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S U M M A R Y
Objectives: To establish the contribution of genetic host factors to the risk of community-acquired
pneumonia (CAP) and nosocomial pneumonia (NP) in the population of the Russian Federation.
Methods: A total of 796 subjects (CAP: 334 patients, 134 controls; NP: 216 critically ill patients with NP,
105 critically ill patients without NP) were included in two case–control studies. We analyzed 13
polymorphisms in 11 genes (IL-6, TNF-a, MBL2, CCR5, NOS3, CYP1A1 (three sites), GSTM1, GSTT1, ABCB1,
ACE, and MTHFR) using a tetra-primer allele-speciﬁc PCR method.
Results: Individual single nucleotide polymorphism (SNP) analysis revealed a strong association
between CYP1A1 rs2606345 and CAP (p = 3.9  105, odds ratio (OR) 0.42, 95% conﬁdence interval (CI)
0.27–0.63). Three genes (CYP1A1, ACE, and IL-6) were identiﬁed that account for part of the increase in
vulnerability to both diseases, CAP and NP. The carriage of three predisposing genotypes versus
protective genotypes increased the CAP risk (p = 0.001, OR 7.01, 95% CI 1.99–24.70) and NP risk
(p = 0.028, OR 4.34, 95% CI 1.15–16.45).
Conclusions: Genetic predisposition to CAP and NP is attributed to the cumulative contribution of
polymorphisms at the CYP1A1, IL-6, and ACE genes, independently of age, gender, causative pathogen,
and the use of mechanical ventilation, in patients in the Russian Federation.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Community-acquired pneumonia (CAP) and nosocomial pneu-
monia (NP) are frequent infectious problems that show no
tendency to a signiﬁcant decrease. Susceptibility to CAP and
critical CAP complications has been studied systematically by
several groups of investigators, and apparent success has been
achieved in the identiﬁcation of polymorphic variants of some host
genes associated with the diversity in the response to CAP. These
are genes critical to the CAP innate immune system,1–16 genes
controlling lung defense against inhaled microorganisms4,17 and
inhibition of ﬁbrinolysis,18 and some others. Genetic variations in
several genes (MBL2, MASP-2, and PAI-1) reported to be associated
with CAP have also been studied in NP patients,19–23 but to our
knowledge there are no publications investigating both CAP and
NP for the same single nucleotide polymorphisms (SNPs).* Corresponding author. Tel.: +7 499 1328958; fax: +7 499 1328962.
E-mail addresses: salnikovalyubov@gmail.com, Salnikova@vigg.ru
(L.E. Salnikova).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.01.005To evaluate candidate host genetic variants predisposing to
CAP and NP, we selected 13 polymorphic variants assigned to 11
different genes. The selection of the genes was based on their
association with molecular pathways probably implicated in CAP
pathogenesis and on literature data. Genes involved in the
immune and inﬂammation response are directly relevant to the
human host defense (IL-6 rs1800795, TNF-a rs1800629, MBL2
rs7096206, CCR5 rs333, and NOS3 rs1799983). Xenobiotic
detoxiﬁcation genes were also included in our study as they
encode enzymes involved in the detoxiﬁcation and excretion of a
broad range of compounds, including products of oxidative stress
and drugs, thereby participating in the general resistance to
exogenous and endogenous harmful metabolites, as well as
in the biotransformation of drugs (CYP1A1 rs2606345, rs4646903,
rs1048943, GSTM1 Ins/del, GSTT1 Ins/del, and ABCB1 rs1045642).
Two additional genes might have an impact on CAP initiation
and progression – the gene of the renin–angiotensin system
ACE (rs4340) and the gene-candidate for occlusive vascular
disease and hyperhomocysteinemia MTHFR (rs1801133), both
disorders possibly affecting augmentation of inﬂammation
processes.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Patients and controls
From January 2008 to October 2011 a total of 334 Russian
Federation patients with CAP, hospitalized at the clinical bases of
the V. A. Negovsky Research Institute of General Reanimatology,
Moscow, Russia, were included in the study. The diagnosis of CAP
was based on the presence of acute symptoms resulting from a
lower respiratory tract infection, conﬁrmed by clinical (cough,
sputum production, auscultatory ﬁndings consistent with pneu-
monia, a temperature of >38 8C or <35 8C), radiological (an
inﬁltrate on chest X-rays), and laboratory (a white blood cell count
of >10  109 cells/l or <4  109 cells/l) data. Hospitalization was
ascertained based on participant self-report and active surveil-
lance by medical personnel.
The control group consisted of 141 unrelated healthy volun-
teers without a previous history of pneumonia.
We selected a group of accident victims who had sustained
severe, mostly life-threatening physical trauma and patients with
acute diseases requiring extensive surgery for the NP study.
Clinical data were collected prospectively. The NP study included
216 patients with nosocomial pneumonia and 105 patients who
did not develop NP during their stay in the hospital. Eighty (76.2%)
patients without NP and 205 (94.9%) patients with NP were
intubated and ventilated. The durations of mechanical ventilation
were signiﬁcantly longer in cases than in controls: 50% of NP
patients were mechanically ventilated over 15 days compared
with only 7% of patients without NP. The diagnosis of pneumonia
was made on the basis of the appearance of a new inﬁltrate on
chest X-ray in the presence of cough, fever, and leukocytosis.
Exclusion criteria for the CAP and NP groups consisted of age
<18 years, lack of informed consent, deﬁned immunodeﬁciency,
corticosteroid administration <6 weeks prior, history of recent
hospitalization (<30 days), chronic respiratory diseases (asthma,
chronic obstructive pulmonary disease, tuberculosis, obstructive
pneumonia caused by neoplasia), malignancy, ﬁnal stage of
chronic disease, decompensated heart failure (New York Heart
Association (NYHA) class IV), decompensated diabetes, severe
neurological deﬁcit (Glasgow coma scale 8), addiction, alcohol-
ism, AIDS, and pregnancy.
The ethnicity of the population in the present study was
primarily (97%) Caucasian, mainly Slavs (81.6–86.1%), among
them Russians (65.7–74.5%) (see tables; more detailed information
is available in the Supplementary Material).
Respiratory ﬂuid samples obtained by endotracheal aspiration
were taken for microbiological documentation of CAP and NP. The
bacteriological examination consisted of Gram stain smears and
cultures. Bronchoalveolar lavage (BAL) ﬂuid was stained and
cultured for aerobic and anaerobic bacteria, fungi (Aspergillus and
Candida species), and mycobacteria. A positive quantitative culture
was deﬁned when bacteria were cultured from BAL samples at a
concentration of 1  105 CFU/ml or more.
The study protocol was approved by the Ethics Committee of V.
A. Negovsky Research Institute of General Reanimatology RAMS
(with institutional review board approval number 2/6/2012) and
adhered to the tenets of the Declaration of Helsinki.
2.2. Genotyping
DNA was isolated from 200 ml of blood using gDNA puriﬁcation
kit Diatom DNA Prep 200 (Isogene Laboratory, Moscow, Russia).
Genotyping was performed using an allele-speciﬁc tetra-primer
PCR developed to genotype a relatively large number of samples in
a cost-effective and time-saving manner. In this method, allele-
speciﬁc DNA products are ampliﬁed by means of applyingappropriately designed two-pair primers (four primers) into an
ordinary PCR tube.24 Ampliﬁcation was carried out in an ABI
thermal cycler using two external and two internal sequence-
speciﬁc primers (Supplementary Material, Table S2) and PCR
MasterMix tubes (Isogene Laboratory, Moscow, Russia), as
previously described.25 The PCR products were then analyzed in
2% agarose gel stained with ethidium bromide. For each SNP, 10% of
randomly taken DNA samples (cases and controls) were genotyped
twice and no discrepancies were observed.
2.3. Statistical analysis
Exact Hardy–Weinberg equilibrium (HWE) tests were per-
formed for each SNP independently using the goodness-of-ﬁt Chi-
square test to compare the observed and expected genotype
frequencies for the CAP, NP, and control groups. Logistic regression
analysis adjusted for age, gender, ethnicity, and the use and
duration of mechanical ventilation was performed to evaluate the
associations between the studied gene polymorphisms and CAP or
NP risk. Odds ratios (ORs) and 95% conﬁdence intervals (CIs) were
calculated using the SNPStats software.26 If one allele of the SNP
was underrepresented among patients it was considered a
protective allele (OR < 1). Reciprocally the second allele in a
two-allele system would be overrepresented among patients and it
would be a risk allele (OR > 1). Three genetic models deﬁned
relative to the minor allele were considered: dominant (minor
homozygotes + heterozygotes vs. major homozygotes), recessive
(minor homozygotes vs. heterozygotes + major homozygotes),
overdominant (minor homozygotes + major homozygotes vs.
heterozygotes).
Multiple SNP statistical analysis was performed using WinSTAT
software (Robert K. Fitch Software, Germany).
WINPEPI test power and sample size calculators were used to
evaluate type II error.27 To detect OR = 2.0 in our sample size for the
CAP study, the test power for the additive model for relative minor
allele frequency 0.06 (rs1048943G) is 39.1% and for minor allele
frequency 0.47 (rs4340Ins) is 91.2% (two-sided Fisher’s test). Test
power in our NP study is 43.3% for relative minor allele frequency
0.1 (rs1048943G) and 79.1% for allele frequency 0.45 (rs4340Del).
3. Results
A total 334 patients with CAP (307 males and 27 females; age
range 18–55 years, mean age 27 years) were included in CAP case–
control study. One hundred forty-one unrelated healthy volunteers
without a previous history of pneumonia were matched by age,
sex, and ethnicity (130 males and 11 females; age range 18–52
years, mean age 29 years). The main demographic and clinical
variables of the patients with CAP and controls are shown in
Table 1.
The NP set comprised 216 patients with nosocomial pneumonia
(176 males and 40 females; age range 18–82 years, mean age 43
years) and 105 patients (83 males and 22 females; age range 19–93
years, mean age 41 years) who did not develop NP during their stay
in the hospital due to severe life-threatening conditions. Controls
were matched by age, sex, ethnicity, and underlying disease
(Table 2).
Microbiological conﬁrmation was achieved in 233 CAP patients.
Streptococcus species were isolated in 149 patients (64% of the
patients with a known causative microorganism), and Streptococcus
pneumoniae was the most common etiologic agent (143 patients,
61.4%). Staphylococcus aureus was identiﬁed in 55 patients with CAP
(23.6%) (Table 1). Microbiological data were available for only 66 NP
patients. Typical nosocomial pathogens that are known to play a role
in the development of NP, including ventilator-associated pneumo-
nia (VAP), were identiﬁed: Gram-negative bacilli (36 patients, 54.5%
Table 1
Characteristics of the community-acquired pneumonia (CAP) and control groups
involved in the study
Feature Control, n (%) CAP, n (%)
Total number 141 334
Age, years 29.1  0.6 26.9  0.8
Sex
Male 130 (92.2) 307 (91.9)
Female 11 (7.8) 27 (8.1)
Ethnicity
Caucasians 138 (97.9) 324 (97.0)
Slavs 115 (81.6) 276 (82.6)
Russian 105 (74.5) 238 (71.3)
Progression
Bilateral - 98 (29.3)
Unilateral - 236 (70.7)
Background diseases -
No - 326 (97.6)
Yesa - 8 (2.4)
Comorbidity -
No 303 (90.7)
Yesb 31 (9.3)
Causative pathogensc - 233 (69.8)
Streptococcal infections - 149 (44.6)
Streptococcus pneumoniae - 143 (42.8)
Streptococcus pyogenes - 3 (0.9)
Other Streptococcus - 3 (0.9)
Staphylococcus aureus - 55 (16.5)
Haemophilus inﬂuenzae - 11 (3.3)
Mycoplasma pneumoniae - 11 (3.3)
Other infectious pathogens - 7 (2.1)
Duration of hospitalization, days - 27.4  10.2
Hospital mortality - 12 (3.6)
a Ischemic cardiopathy, diabetes, obesity.
b Most frequently purulent antritis (51.61%).
c In patients with mixed CAP (n = 43; 12.9%) the most prevalent microorganism is
speciﬁed.
Table 2
Characteristics of the nosocomial pneumonia (NP) and non-NP (control) groups
involved in the study
Characteristics Patients
without
NP, n (%)
Patients
with NP,
n (%)
Total number 105 216
Age, years 41.0  1.6 43.0  2.0
Sex
Male 83 (79.1) 176 (81.5)
Female 22 (20.9) 40 (18.5)
Ethnicity
Caucasian 105 (100) 213 (98.6)
Slav 86 (81.9) 186 (86.1)
Russian 69 (65.7) 152 (70.4)
Background diseases
No 89 (84.8) 156 (72.2)
Yes 16 (15.2) 60 (27.8)
Cardiovascular diseasesa 3 (2.9) 19 (8.8)
Type 2 diabetes 2 (1.9) 7 (3.2)
Obesity 1 (0.95) 10 (4.6)
Neurological pathology 1 (0.95) 7 (3.2)
Gastric ulcer 2 (1.9) 4 (1.85)
Duodenal ulcer 1 (0.95) 5 (2.3)
Urolithiasis 2 (1.9) 4 (1.85)
Cholelithiasis 4 (3.8) 4 (1.85)
Underlying disease
Severe combined trauma/wound 30/21 (48.6) 109/34 (66.2)
Pancreatonecrosis 8 (7.6) 15 (6.9)
Bowel obstruction 18 (17.1) 33 (15.3)
Acute phlegmonous and gangrenous
appendicitis
2 (1.9) 2 (0.9)
Destructive cholecystitis 9 (8.6) 3 (1.4)
Hollow organ perforation 10 (9.5) 4 (1.85)
Purulent inﬂammatory diseases of
the skin, subcutaneous tissue,
and soft tissue
4 (3.8) 4 (1.85)
Renal carbuncle 3 (2.9) 5 (2.3)
Acute violation of cerebral circulation (0.0) 3 (1.4)
Table 2 (Continued )
Characteristics Patients
without
NP, n (%)
Patients
with NP,
n (%)
Lacunar tonsillitis, retropharyngeal
abscess
(0.0) 1 (0.5)
Suppurative submandibular
lymphadenitis
(0.0) 1 (0.5)
Purulent sphenoiditis (0.0) 1 (0.5)
Pericarditis (0.0) 1 (0.5)
Complications (of basic disease)
No 44 (41.9) (0.0)
Yes 61 (58.1) 216 (100.0)
Major complications
Nosocomial pneumonia (0.0) 216 (100.0)
Peritonitis 28 (26.7) 49 (22.7)
Intra-abdominal abscesses 5 (4.8) 6 (2.8)
Anastomotic failure (0.0) 8 (3.7)
Lung abscesses (0.0) 17 (7.9)
Pleural empyema (0.0) 13 (6.0)
Wound suppuration 3 (2.9) 3 (1.3)
Post-traumatic osteomyelitis 2 (1.9) 4 (1.85)
Secondary meningoencephalitis 2 (1.9) 4 (1.85)
Mediastinitis 1 (0.95) 8 (3.7)
Tracheoesophageal ﬁstula (0.0) 2 (0.9)
Severe sepsis 2 (1.9) 56 (25.9)
Septic shock 2 (1.9) 15 (6.9)
Multiple organ failure 5 (4.8) 74 (34.3)
Acute respiratory distress syndrome 3 (2.9) 21 (9.7)
Pulmonary embolism 3 (2.9) 5 (2.3)
Brain abscesses 1 (0.95) (0.0)
Pleurisy 4 (3.8) 23 (10.7)
Combined complications 7 (6.7) 131 (60.7)
Infectious pathogens - 66 (30.6)
Pseudomonas aeruginosa - 7 (3.2)
Klebsiella pneumoniae - 9 (4.2)
Staphylococcus aureus - 12 (5.6)
Escherichia coli - 7 (3.2)
Pseudomonas aeruginosa +
Acinetobacter baumannii
- 13 (6.0)
Pseudomonas aeruginosa +
methicillin-resistant
Staphylococcus aureus +
Acinetobacter baumannii
- 11 (5.1)
Klebsiella pneumoniae +
Staphylococcus aureus +
Acinetobacter baumannii
- 7 (3.2)
Use of mechanical ventilation
No 25 (23.8) 11 (5.1)
Yes 80 (76.2) 205 (94.9)
Duration of mechanical
ventilation, days
21.9  9.2 5.3  1.3
<5 days 59 (56.2) 40 (18.5)
5–15 days 14 (13.3) 57 (26.4)
>15 days 7 (6.7) 108 (5.0)
ICU admission
No 4 (3.8) 9 (4.2)
Yes 101 (96.2) 207 (95.8)
Duration of hospitalization, days 41.3  19.6 49.9  18.9
Hospital mortality 3 (2.9) 80 (37.0)
ICU, intensive care unit.
a Ischemic cardiopathy, essential hypertension, widespread atherosclerosis,
coronary artery bypass.
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positive bacteria (12 patients, 18.2%), and mixed cases (18 patients,
27.3%) (Table 2).
3.1. Individual SNP analysis in the CAP association study
Thirteen polymorphic variants (11 SNPs and two copy number
variations (CNV) – GSTM1 and GSTT1) were genotyped in CAP and
control subjects from the Russian population. SNPs were analyzed
for HWE. In the control group the genotype frequencies of all
studied variations were in HWE (Table 3). For rs2606345 and
Table 3
Distribution of genotypes among the community-acquired pneumonia (CAP) and control groups
Genes and genotypes Control subjects,
n (%)
CAP, n (%) Crude analysis Adjusted analysis (adjusted by age, sex,
and ethnicity)
p-Valuea (genetic model)b OR, 95% CI p-Valuea (genetic model)b OR, 95% CI
Xenobiotic detoxiﬁcation
CYP1A1
rs2606345
n = 134
HWPc= 0.72
n = 334
HWP = 0.0025
T/T
T/G
G/G
46 (34.3)
63 (47.0)
25 (18.7)
186 (55.7)
111 (33.2)
37 (11.1)
3.9  105 (dom) Reference
0.42, 0.27–0.63
3.87  105 (dom) Reference
0.41, 0.27–0.63
CYP1A1
rs4646903
n = 131
HWP = 0.22
n = 323
HWP = 0.5
T/T
T/C
C/C
98 (74.8)
33 (25.2)
0 (0.0)
265 (82.0)
57 (17.7)
1 (0.3)
0.086 (dom) Reference
0.65, 0.40–1.06
0.094 (dom) Reference
0.65, 0.40–1.07
CYP1A1
rs1048943
Ile462Val
n = 132
HWP = 1.0
n = 323
HWP = 1.0
A/A
A/G
G/G
124 (93.9)
8 (6.1)
0 (0.0)
291 (90.1)
32 (9.9)
0 (0.0)
0.17 (dom) Reference
1.70, 0.76–3.80
0.14 (dom) Reference
1.80, 0.80–4.05
GSTM1
Del(D/D)-
Ins (I/*)
n = 140 n = 331
HWP (N/A) HWP (NA)
D/D
I/*
78 (55.7)
62 (44.3)
134 (40.5)
197 (59.5)
0.0024 (N/A) Reference
1.85, 1.24–2.76
0.0021 (N/A) Reference
1.90, 1.26–2.86
GSTT1
Del(D/D)-
Ins (I/*)
n = 140 n = 331
HWP (N/A) HWP (N/A)
I/*
D/D
118 (84.3)
22 (15.7)
268 (80.9)
63 (19.1)
0.39 (N/A) Reference
0.79, 0.47–1.35
0.42 (N/A) Reference
0.80, 0.46–1.38
ABCB1
rs1045642
Ile1145 =
n = 141
HWP = 0.31
n = 333
HWP = 0.08
T/T
T/C
C/C
47 (33.3)
63 (44.7)
31 (22.0)
140 (42.0)
140 (42.0)
53 (16.0)
0.074 (dom) Reference
0.69, 0.46–1.04
0.065 (dom) Reference
0.67, 0.44–1.03
Immune response regulation and inﬂammation
IL-6
rs1800795
n = 139
HWP = 0.061
n = 322
HWP = 0.31
G/G
G/C
C/C
37 (26.6)
80 (57.6)
22 (15.8)
103 (32.0)
150 (46.6)
69 (21.4)
0.033 (od) Reference
0.64, 0.43–0.96
0.053 (od) Reference
0.67, 0.44–1.01
TNF-a
rs1800629
n = 139
HWP = 0.074
n = 321
HWP = 0.8
G/G
G/A
A/A
100 (71.9)
39 (28.1)
0 (0.0)
248 (77.3)
68 (21.2)
5 (1.5)
0.23 (dom) Reference
0.75, 0.48–1.19
0.27 (dom) Reference
0.77, 0.49–1.22
MBL2
rs7096206
n = 120
HWP = 0.51
n = 277
HWP = 0.39
C/C
G/G
85 (70.8)
31 (25.8)
4 (3.3)
194 (70.0)
73 (26.4)
10 (3.6)
0.87 (dom) Reference
1.04, 0.65–1.66
0.93 (dom) Reference
1.02, 0.63–1.66
CCR5
Del32
rs333
n = 141
HWP = 1.0
n = 319
HWP = 1.0
I/I
I/D
D/D
113 (80.1)
27 (19.2)
1 (0.7)
281 (88.1)
37 (11.6)
1 (0.3)
0.029 (dom) Reference
0.55, 0.32–0.93
0.0087 (dom) Reference
0.47, 0.27–0.82
NOS3
rs1799983
Asp298Glu
n = 141
HWP = 0.15
n = 321
HWP = 0.76
G/G
G/T
T/T
67 (47.5)
66 (46.8)
8 (5.7)
185 (57.6)
116 (36.1)
20 (6.2)
0.031 (od) Reference
0.64, 0.43–0.96
0.016 (od) Reference
0.60, 0.40–0.91
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Table 3 (Continued )
Genes and genotypes Control subjects,
n (%)
CAP, n (%) Crude analysis Adjusted analysis (adjusted by age, sex,
and ethnicity)
p-Valuea (genetic model)b OR, 95% CI p-Valuea (genetic model)b OR, 95% CI
Renin–angiotensin system
ACE
rs4340
Alu-287 bp
n = 141
HWP = 1.0
n = 321
HWP = 0.014
D/D
I/D
I/I
30 (21.3)
70 (49.7)
41 (29.1)
105 (32.8)
137 (42.8)
78 (24.4)
0.011 (dom) Reference
0.55, 0.35–0.88
0.0052 (dom) Reference
0.52, 0.32–0.83
Occlusive vascular disease
MTHFR
rs1801133
Ala222Val
n = 131
HWP = 0.32
n = 316
HWP = 0.53
C/C
C/T
T/T
56 (42.8)
64 (48.9)
11 (8.4)
134 (42.4)
148 (46.8)
34 (10.8)
0.44 (rec) Reference
1.32, 0.64–2.68
0.49 (rec) Reference
1.29, 0.62–2.66
OR, odds ratio; CI, conﬁdence interval; N/A, Not applicable.
Genotypes associated with a response in accordance with OR (protective if OR < 1, susceptible if OR > 1) are in bold-type.
a Signiﬁcant p-values <0.05.
b The genetic model: rec, recessive; dom, dominant; od, overdominant (for the overdominant model the reference genotype is major homozygote + minor homozygote).
c Hardy–Weinberg probability (a probability for the deviation between observed and expected numbers for the dominant homozygotes, the heterozygotes, and the
recessive homozygotes in a two-allele system).
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more detailed analysis showed that this was linked to CAP
predisposition. We revealed CAP susceptibility genes in the crude
analysis (CYP1A1 rs2606345, GSTM1, IL-6, NOS3, CCR5, and ACE).
Multivariate analysis adjusted for age, gender, and ethnicity
showed that the abovementioned association signals became more
pronounced, with only IL-6 demonstrating a marginally signiﬁcant
p-value. In the CAP group we observed signiﬁcant over-represen-
tation of the CYP1A1 rs2606345T/T and ACE rs4340 D/D risk
genotypes relative to the control group.
3.2. Individual SNP analysis in the NP association study
The same polymorphic variants were genotyped in two other
groups from the Russian population: 216 patients with NP and 105
patients who did not develop NP during their stay in the hospital
(Table 4). Genotype frequencies of the studied polymorphisms in
the control group were in HWE. A signiﬁcant IL-6 heterozygote
deﬁciency against the null hypothesis of HWE was observed in the
NP group. These data are in line with the protective effect of
heterozygotes found by a logistic regression analysis for the
overdominant model. The ACE gene also showed an association
with NP in the crude model. Regression analysis adjusted for age,
sex, ethnicity, and duration of mechanical ventilation (if applied)
showed that these ﬁndings remained signiﬁcant for IL-6 and ACE.
Another gene, CYP1A1 (rs2606345), appeared as a susceptibility
gene with a marginally signiﬁcant association with NP (p = 0.051).
3.3. Bonferroni correction for multiple comparisons
To exclude false-positive associations with disease, we used the
Bonferroni correction for multiple comparisons. Signiﬁcant p-
values were multiplied by the number of studied polymorphisms.
The p-value after Bonferroni correction remained signiﬁcant for
the CYP1A1 gene (rs2606345): pbonf = 0.00051, and for the GSTM1
gene: pbonf = 0.031, in the CAP case–control study.
3.4. CAP and NP association studies in Slavs
Individuals with ancestors other than Slav were excluded from
the case and control groups (Supplementary Material, Table S3).Multivariate analysis adjusted for age, gender (and use of
mechanical ventilation in the NP set) showed that CYP1A1 TG–
GG carriers (rs2606345) were signiﬁcantly less likely to develop
CAP and NP. The frequency of the ACE II-ID genotypes was
signiﬁcantly greater among controls compared with CAP patients.
In the NP set, ACE I/I homozygous individuals also showed a lower
disease incidence. A protective effect for IL-6 heterozygotes was
revealed in the CAP (trend p = 0.056) and NP studies. Signiﬁcant
differences in the frequency distributions among CAP cases and
controls were also observed for GSTM1 and NOS3 genes.
3.5. Analysis of independent prognostic risk factors of CAP and NP
Since the inﬂammatory response and the immune response
may vary depending on the microorganism, the role of the SNPs
showing p-values of <0.1 in the CAP set was analyzed in the groups
of CAP patients with known causative microorganisms. A total of
149 patients with streptococcal infections and 55 patients with
staphylococcal infections were further analyzed (Table 5). Multi-
variate analysis adjusted for age, gender, and ethnicity conﬁrmed
that CYP1A1 T/G–G/G genotypes and ACE Ins I/I-I/D genotypes were
the independent protective factors for streptococcal CAP and for
staphylococcal CAP. A marginally signiﬁcant association was also
found between the IL-6 gene and streptococcal CAP risk. The small
sample size in the staphylococcal CAP group results in wide
conﬁdence intervals and a p-value that is outside the signiﬁcance
level (p = 0.067). Multivariate regression also identiﬁed GSTM1,
CCR5, and NOS3 genotypes as having signiﬁcant effects on
streptococcal CAP susceptibility. In contrast we found not even
a trend (p < 0.15) for an association of these polymorphic variants
with staphylococcal CAP (Table 5).
Additionally we compared the distributions of CYP1A1
(rs2606345), ACE, and IL-6 genotypes in the subgroups of patients
with streptococcal CAP and staphylococcal CAP. The frequencies of
genotypes did not differ signiﬁcantly in patients with different
causative microorganisms (Chi-square = 0.95, p = 0.62; Chi-
square = 1.9, p = 0.39; Chi-square = 1.1, p = 0.59, respectively).
With regard to the speciﬁc NP causative microorganisms we
could not perform the association analysis because of the small
numbers of patients in the groups. We compared the genotype
distributions among NP patients with Gram-negative bacilli (36
Table 4
Distribution of genotypes among the nosocomial pneumonia (NP) and control groups
Genes and genotypes Non-NP, n (%) NP, n (%) Crude analysis Adjusted analysis (adjusted by age,
sex, ethnicity, and duration of
mechanical ventilation)
p-Valuea
(genetic model)b
OR, 95% CI p-Valuea
(genetic model)b
OR, 95% CI
Xenobiotic detoxiﬁcation
CYP1A1
rs2606345
n = 102
HWPc= 0.22
n = 209
HWP = 0.88
T/T
T/G
G/G
32 (31.4)
56 (54.9)
14 (13.7)
88 (42.1)
97 (46.4)
24 (11.4)
0.066 (dom) Reference
0.63, 0.38–1.04
0.051 (dom) Reference
0.60, 0.35–1.01
CYP1A1
rs4646903
n = 94
HWP = 0.59
n = 186
HWP = 0.48
T/T
T/C
C/C
74 (78.7)
20 (21.3)
0 (0.0)
144 (77.4)
41 (22.0)
1 (0.5)
0.8 (dom) Reference
1.08, 0.59–1.97
0.92 (dom) Reference
1.04, 0.47–2.29
CYP1A1
rs1048943
Ile462Val
n = 95
HWP = 1.0
n = 186
HWP = 1.0
A/A
A/G
G/G
85 (89.5)
10 (10.5)
0 (0.0)
171 (91.9)
15 (8.1)
0 (0.0)
0.5 (dom) Reference
0.75, 0.32–1.73
0.17 (dom) Reference
0.39, 0.10–1.53
GSTM1
Del(D/D)-
Ins (I/*)
n = 104
HWP (N/A)
n = 208
HWP (N/A)
D/D
I/*
48 (46.2)
56 (53.8)
94 (45.2)
114 (54.8)
0.87 (N/A) Reference
1.04, 0.65–1.67
0.50 (N/A) Reference
1.22, 0.68–2.21
GSTT1
Del(D/D)-
Ins (I/*)
n = 104
HWP (N/A)
n = 208
HWP (N/A)
D/D
I/*
13 (12.5)
91 (87.5)
31 (14.9)
177 (85.1)
0.56 (N/A) Reference
0.82, 0.41–1.63
0.47 (N/A) Reference
0.74, 0.32–1.71
ABCB1
rs1045642
Ile1145 =
n = 105
HWP = 0.23
n = 216
HWP = 0.32
T/T
T/C
C/C
38 (36.2)
45 (42.9)
22 (20.9)
72 (33.3)
112 (51.9)
32 (14.8)
0.17 (rec) Reference
0.66, 0.36–1.20
0.35 (rec) Reference
0.70, 0.34–1.46
Immune response regulation and inﬂammation
IL-6
rs1800795
n = 100
HWP = 0.14
n = 206
HWP = 0.009
G/G
G/C
C/C
32 (32.0)
56 (56.0)
12 (12.0)
83 (40.3)
81 (39.3)
42 (20.4)
0.006 (od) Reference
0.51, 0.31–0.83
0.04 (od) Reference
0.53, 0.29–0.98
TNF-a
rs1800629
n = 105
HWP = 0.35
n = 208
HWP = 0.23
G/G
G/A
A/A
81 (77.1)
24 (22.9)
0 (0.0)
167 (80.3)
41 (19.7)
0 (0.0)
0.52 (dom) Reference
0.83, 0.47–1.46
0.38 (dom) Reference
0.71, 0.33–1.52
MBL2
rs7096206
n = 80
HWP = 0.34
n = 151
HWP = 0.55
C/C
C/G
G/G
59 (73.8)
21 (26.2)
0 (0.0)
107 (70.9)
39 (25.8)
5 (3.3)
0.64 (dom) Reference
1.16, 0.31–2.12
0.91 (dom) Reference
0.95, 0.41–2.23
CCR5
Del32
rs333
n = 105
HWP = 0.59
n = 208
HWP = 0.021
I/I
I/D
D/D
85 (80.9)
20 (19.1)
0 (0.0)
174 (83.7)
29 (13.9)
5 (2.4)
0.55 (dom) Reference
0.83, 0.45–1.53
0.19 (dom) Reference
0.60, 0.28–1.29
NOS3
rs1799983
Asp298Glu
n = 105
HWP = 0.79
n = 209
HWP = 0.33
G/G
G/T
T/T
59 (56.2)
41 (39.0)
5 (4.8)
98 (46.9)
95 (45.4)
16 (7.7)
0.12 (dom) Reference
1.45, 0.91–2.33
0.52 (dom) Reference
1.21, 0.68–2.17
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Table 4 (Continued )
Genes and genotypes Non-NP, n (%) NP, n (%) Crude analysis Adjusted analysis (adjusted by age,
sex, ethnicity, and duration of
mechanical ventilation)
p-Valuea
(genetic model)b
OR, 95% CI p-Valuea
(genetic model)b
OR, 95% CI
Renin–angiotensin system
ACE
rs4340
Alu-287 bp
n = 105
HWP = 0.24
n = 208
HWP = 0.89
D/D
I/D
I/I
24 (22.9)
46 (43.8)
35 (33.3)
59 (28.4)
102 (49.0)
47 (22.6)
0.044 (rec) Reference
0.58, 0.35–0.98
0.03 (rec) Reference
0.47, 0.24–0.93
Occlusive vascular disease
MTHFR
rs1801133
Ala222Val
n = 94
HWP = 0.48
n = 184
HWP = 0.5
C/C
C/T
T/T
41 (43.6)
45 (47.9)
8 (8.5)
83 (45.11)
85 (46.20)
16 (8.70)
0.81 (dom) Reference
0.94, 0.57–1.55
0.81 (dom) Reference
1.08, 0.57–2.07
OR, odds ratio; CI, conﬁdence interval; N/A,.
Genotypes associated with a response in accordance with OR (protective if OR < 1, susceptible if OR > 1) are in bold-type.
a Signiﬁcant p-values <0.05.
b The genetic model: rec, recessive; dom, dominant; od, overdominant (for the overdominant model the reference genotype is major homozygote + minor homozygote).
c Hardy–Weinberg probability (a probability for the deviation between observed and expected numbers for the dominant homozygotes, the heterozygotes, and the
recessive homozygotes in a two-allele system).
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ganism), Gram-positive bacteria (S. aureus; 12 patients, 18.2%), and
mixed Gram-negative and Gram-positive infections (18 patients,
27.3%). Three SNPs showing p-values of <0.1 in the NP set (Table 4)
were analyzed. The distribution of CYP1A1 (rs2606345), ACE, and
IL-6 genotypes did not differ among the three groups of NP patients
with different infectious pathogens (Chi-square = 1.6, p = 0.81;
Chi-square = 4.7, p = 0.32; Chi-square = 0.4, p = 0.98, respectively).
Mechanical ventilation is the key risk factor for the develop-
ment of NP. There was no signiﬁcant difference in the distribution
of genotype frequency among the four groups of NP patients with
different durations of mechanical ventilation (no ventilation, less
than 5 days, 5–15 days, more than 15 days): for CYP1A1
(rs2606345) Chi-square = 1.6, p = 0.95; for ACE Chi-square = 5.6,
p = 0.48; for IL-6 Chi-square = 2.5, p = 0.87. As there were
mechanically ventilated patients in both NP groups (cases and
non-NP patients), we then analyzed the genotype–covariate
(duration of mechanical ventilation) interaction. The interaction
p-value was insigniﬁcant: for CYP1A1 (rs2606345) pinteraction = 0.7,
for ACE pinteraction = 0.14, for IL-6 pinteraction = 0.10.
NP patients were grouped by age 65 years (n = 37) and <65
years (n = 179). The difference in the distribution of genotypes was
non-signiﬁcant in the age subgroups: for CYP1A1 (rs2606345) Chi-
square = 2.56, p = 0.28; for ACE Chi-square = 0.72, p = 0.70; for IL-6
Chi-square = 3.29, p = 0.19. The interaction analysis also showed
no signiﬁcant interaction between genotype and age: for CYP1A1
(rs2606345) pinteraction = 0.32, for ACE pinteraction = 0.10, for IL-6
pinteraction = 0.97.
3.6. Multiplicative genetic model and CAP and NP
We further explored the multiplicative genetic model of the
genes demonstrating an association with both CAP and NP risk in
all sets with a p-value of <0.1. Figure 1 shows the effect of having
three risk genotypes on modulating the CAP and NP risk. The
carriage of three predisposing genotypes (CYP1A1 rs2606345T/T
and ACE rs4340D/D and IL-6 rs1800795G/G+C/C) versus protective
genotypes (CYP1A1 rs2606345G/G+T/G and ACE rs4340I/I+I/D and
IL-6 rs1800795G/C) increased the CAP risk (p = 0.001, OR 7.01, 95%CI 1.99–24.70) and the NP risk (p = 0.028, OR 4.34, 95% CI 1.15–
16.45). The prognostic value of this genetic model is characterized
by a sensitivity of 36.2%, speciﬁcity of 92.5%, and balancing
accuracy of 64.4% for CAP, and a sensitivity of 32.3%, speciﬁcity of
90.0%, and balancing accuracy of 61.5% for NP.
3.7. Analysis of genotype frequencies in NP subgroups with or without
a poor outcome
Since the majority of NP patients also had sepsis/septic shock,
acute respiratory distress syndrome (ARDS), peritonitis, or
multiple organ failure (MOF), we divided our NP group into two
subgroups: absence of a poor outcome (n = 85) and presence of a
poor outcome (n = 131). We compared the distribution of CYP1A1
rs2606345, IL-6, and ACE genotypes in these subgroups to get an
answer to the question ‘‘Are our ﬁndings indeed linked only to
pneumonia, and not to a poor outcome?’’ The frequencies of
genotypes did not differ in NP patients with and without a poor
outcome, even at a trend level (Supplementary Material, Table
S4). Therefore we can conclude that the observed associations are
indeed between gene polymorphisms and pneumonia per se.
4. Discussion
In this study we found that the CYP1A1, ACE, and IL-6 variant
genotypes were signiﬁcantly associated with CAP and NP. The
relevance of the observed association was indirectly conﬁrmed by
a similar character of association in the CAP and NP groups. These
ﬁndings were reafﬁrmed by departures from HWE for the genes
associated with CAP and NP. Alleles within genotypes that confer
greater susceptibilities are represented in the sample at dispro-
portionally high rates. Disequilibrium is expected to be greatest at
the disease-susceptibility locus itself, since this is the factor that
determines the selection criterion.28
The main ﬁnding of this study was the association of the gene
CYP1A1 (rs2606345), encoding an enzyme of the phase I
detoxiﬁcation system, with CAP. The same trend was also revealed
for NP. CYP1A1 is the actively studied pulmonary CYP gene
regulating enzyme, expressed mainly in the epithelium of the
Table 5
The distribution of genotypes among CAP patients with different causative microorganisms and controls
Genes and genotypes Control subjects,
n (%)
CAP with
streptococcal
infection, n (%)
Adjusted for age, sex,
and ethnicity
OR (95% CI)
p-Valuea (genetic model)b
CAP with
staphylococcal
infection, n (%)
Adjusted for age,
sex and ethnicity
OR (95% CI)
p-Valuea (genetic model)b
CYP1A1
rs2606345
n = 134 n = 149 n = 46
T/T
T/G
G/G
46 (34.3)
63 (47.0)
25 (18.7)
84 (56.4)
46 (30.9)
19 (12.8)
Reference
0.36 (0.21–0.61)
p = 9.1  105 (dom)
25 (54.4)
17 (37.0)
4 (8.7)
Reference
0.39 (0.26–0.99)
p = 0.021 (dom)
CYP1A1
rs4646903
n = 131 n = 148 n = 44
T/T
T/C
C/C
98 (74.8)
33 (25.2)
120 (81.1)
28 (18.9)
Reference
0.62 (0.33–1.18)
38 (86.4)
5 (11.4)
Reference
0.35 (0.11–1.14)
0 (0.0) 0 (0.0) p = 0.15 (dom) 1 (2.3) p = 0.06 (dom)
GSTM1
Del(D/D)-
Ins (I/*)
n = 140 n = 149 n = 46
D/D
I/*
78 (55.7)
62 (44.3)
57 (38.3)
92 (61.7)
Reference
2.23 (1.33–3.76)
23 (52.3)
21 (47.7)
Reference
1.14 (0.52–2.50)
p = 0.0022 (N/A) p = 0.75 (N/A)
ABCB1
rs1045642
Ile1145 =
n = 141 n = 147 n = 46
T/T 47 (33.3) 63 (42.9) Reference 15 (32.6) Reference
T/C 63 (44.7) 60 (40.8) 0.72 (0.43–1.21) 24 (52.2) 0.73 (0.26–2.09)
C/C 31 (22.0) 24 (16.3) p = 0.21 (dom) 7 (15.2) p = 0.56 (rec)
IL-6
rs1800795
n = 139 n = 148 n = 44
G/G 37 (26.6) 47 (31.8) Reference 14 (31.8) Reference
G/C 80 (57.5) 68 (46.0) 0.60 (0.36–1.0) 23 (52.3) 0.45 (0.19–1.05)
C/C 22 (15.8) 33 (22.3) p = 0.05 (od) 7 (15.9) p = 0.067 (dom)
CCR5
Del32
rs333
n = 141 n = 147 n = 43
I/I 113 (80.1) 132 (89.8) Reference 32 (74.4) Reference
I/D 27 (19.1) 15 (10.2) 0.35 (0.16–0.76) 11 (25.6) 1.33 (0.52–3.43)
D/D 1 (0.7) 0 (0.0) p = 0.0056 (dom) 0 (0.0) p = 0.56
NOS3
rs1799983
Asp298Glu
n = 141 n = 142 n = 44
G/G 67 (47.5) 86 (60.6) Reference 21 (46.7) Reference
G/T 66 (46.8) 49 (34.5) 0.55 (0.33–0.92) 23 (51.1) 0.83 (0.38–1.82)
T/T 8 (5.7) 7 (4.9) p = 0.023 (od) 1 (2.2) p = 0.65 (dom)
ACE
rs4340
Alu-287 bp
n = 141 n = 148 n = 43
D/D 30 (21.3) 51 (34.5) Reference 14 (32.6) Reference
I/D 70 (49.6) 59 (39.9) 0.49 (0.28–0.86) 17 (39.5) 0.41 (0.18–0.98)
I/I 41 (29.1) 38 (25.7) p = 0.012 (dom) 12 (27.9) p = 0.047 (dom)
OR, odds ratio; CI, conﬁdence interval; N/A,.
Genotypes associated with a response in accordance with OR (protective if OR < 1, susceptible if OR > 1) are in bold-type.
a Signiﬁcant p-values <0.05.
b The genetic model: rec, recessive; dom, dominant; od, overdominant (for the overdominant model the reference genotype is major homozygote + minor homozygote).
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alveolar epithelium, with high inter-individual variability.29 It has
been reported that SNP rs2606345, associated with CAP in our
study, is located in the ﬁrst intron of the gene, but has a functional
character up-regulating CYP1A1 activity for the T or G allele
correspondingly in the absence or in the presence of the speciﬁc
substrates (Polycyclic aromatic hydrocarbon (PAH), polychlori-
nated biphenyls (PCBs), and other chemicals capable of binding to
and activating the Ah receptor).30,31
In recent years, the genetic determinants of individual differ-
ences in CYP1A1 expression and their association with lung
carcinogenesis have been examined widely (10 meta-analyses
according to the HuGE Navigator website, http://hugenavigator.net/HuGEwiki/index.php/HuGE_Navigator), but to our knowledge no
works have examined the possible role of CYP1A1 in lung
inﬂammation. Meanwhile proinﬂammatory cytokines dramatically
down-regulate CYP1A1 expression, disrupting the balance in
expression of CYP family 1 enzymes, increasing the genotoxic
effects of substrates and inducing apoptosis.32 Proinﬂammatory
cytokines inhibit apoptotic cell clearance in the lung, further
exacerbating acute inﬂammation.33 Thus we can suggest that
genetically determined alterations in CYP1A1 activity could
contribute to the pathogenesis of lung inﬂammation.
We also detected the protective effect of ACE insertion in both
the CAP and NP groups. The involvement of the renin–angiotensin
system in the pathogenesis and evolution of pneumonia has gained
Figure 1. Relative frequency distribution by the multiplicative risk genotype in the
community-acquired pneumonia (CAP) and nosocomial pneumonia (NP) sets. The
mean and standard error (SE) of relative frequencies are plotted by the risk
genotype, so that percentages of cases with CAP or NP (1) and matched control
subjects (0) carrying the unfavorable genotype are shown.
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inhibitors.34 According to a meta-analysis, the ACE I/D polymor-
phism contributed to the risk of ACE insertion-related cough in East
Asians but a negative association was observed in Caucasians.35
The I/D polymorphism in intron 16 of the ACE gene is associated
with plasma ACE levels being the highest for the D/D carriers36 and
with degradation of bradykinin in the circulation.37 The D/D
genotype carriers have higher serum levels of the proinﬂammatory
angiotensin II.38 By current data, the functional character of the I/D
polymorphism might be indirect, being a result of linkage
disequilibrium with an allele G2350A.39 It was shown that the
ACE D allele is an independent risk factor for fatal pneumonia in an
elderly Asian population,40 but not in an elderly Dutch white
population.41 We submit results conﬁrming that the ACE D allele is
a risk factor with low penetrance for CAP and NP in a population of
the Russian Federation.
The carriage of IL-6 174 homozygous genotypes G/G and C/C
(rs1800795) was associated with CAP and NP risk. According to
Terry et al., the IL-6 174G/C polymorphism affects transcription by
altering the serum levels of IL-6, with the C allele associated with
signiﬁcantly lower levels of plasma IL-6.42 The results of the
association studies are controversial as they show the deleterious
effects of the minor allele IL-6 174C,1,11 the absence of associa-
tion,43,44 and even suggest its protective role.45 An interesting
ﬁnding of the present study was the protective effect of the IL-
6 174G>C (rs1800795) heterozygote, which was observed in both
the CAP and NP studies. One of the many reasons for the
inconsistent results in association studies might be molecular
heterosis, which is rather common in humans.46 Heterozygosity
may facilitate the dynamic balance between proinﬂammatory and
anti-inﬂammatory factors, thus providing better defense against
exposure to a wider range of causative agents, exogenous and
endogenous pathogens.
The study presented some limitations that should be addressed.
All the polymorphisms were analyzed in the entire CAP and NP
cohorts. The role of the SNPs showing p-values of <0.1 in the CAP
set was also analyzed in the groups of CAP patients with known
causative microorganisms. The microbial diversity of NP was
higher and typical members of different phylogenetic lineages
were detected. A wider range of pathogens and a large number of
polymicrobial cases did not allow us to perform a stratiﬁcation
analysis of subgroups in the NP set, but the presented quantitative
and qualitative spectrum of causative agents of NP is similar to that
of other clinical series.47In summary genotype analyses have not shown any signiﬁcant
difference regarding CAP and NP in models non-adjusted or
adjusted for independent covariates (age, sex, ethnicity, and the
use and duration of mechanical ventilation). In addition the
frequencies of CYP1A1, ACE, and IL-6 genotypes did not differ
between CAP patients with speciﬁc causative pathogens, as well as
between NP patients with known infectious agents. We next
assessed the genotype distributions in NP patients by age and use
and duration of mechanical ventilation and tested the genotype–
covariate interaction. Genotype frequencies were not different in
the subgroups and the genotype–covariate interaction was
insigniﬁcant. This study revealed that individuals bearing CYP1A1
rs2606345T/T, ACE rs4340Del/Del, and IL-6 rs1800795G/G+C/C
genotypes had a higher susceptibility to CAP and NP. Carriage of
three risk genotypes in these genes imposed considerably on the
risk of both CAP and NP, independently of age, gender, type of
causative pathogen, and the use of mechanical ventilation in
patients from the Russian Federation. The strongest new associa-
tion was for CYP1A1 (rs2606345) with susceptibility to CAP.
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